Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066352 · ClinicalTrials.gov registry record · Phase 2
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase 2 study, sponsored by University Health Network, Toronto.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00066352: Completed Phase 2 study, sponsored by University Health Network, Toronto.
NCT00066352 is a Phase 2 study that has completed, run by University Health Network, Toronto. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00066352, a Phase 2 study, has completed, sponsored by University Health Network, Toronto.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with advanced or metastatic transitional cell cancer of the bladder, renal pelvis, or ureter.
Interventions
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-09 |
| Phase | Phase 2 |
What the finished NCT00066352 record still lists
NCT00066352 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which bortezomib is the first listed.
NCT00066352 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00066352 about?
NCT00066352 is a clinical study titled "Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter". RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with advanced or metastatic transitional cell cancer of the bladder, renal pelvis, or ureter.
What is the current status of trial NCT00066352?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-09.
What interventions are being tested in trial NCT00066352?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00066352?
This trial is sponsored by University Health Network, Toronto, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia